Production (Stage)
Bicycle Therapeutics plc
BCYC
$8.05
-$0.05-0.62%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -48.91% | -30.44% | -50.00% | -17.86% | 298.90% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -48.91% | -30.44% | -50.00% | -17.86% | 298.90% |
| Cost of Revenue | 73.83% | -218.89% | 19.59% | 3.11% | 9.73% |
| Gross Profit | -252.52% | 248.90% | -30.94% | -12.40% | 46.61% |
| SG&A Expenses | 25.19% | 81.96% | 16.11% | 1.98% | 9.75% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 56.46% | 19.82% | 18.47% | 2.75% | 9.74% |
| Operating Income | -121.35% | -24.76% | -25.69% | -8.20% | 24.13% |
| Income Before Tax | -129.78% | -8.52% | -13.91% | 7.94% | 32.18% |
| Income Tax Expenses | -210.57% | -438.13% | -251.76% | 122.24% | 43.37% |
| Earnings from Continuing Operations | -128.72% | -5.61% | -1.81% | 6.55% | 32.00% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -128.72% | -5.61% | -1.81% | 6.55% | 32.00% |
| EBIT | -121.35% | -24.76% | -25.69% | -8.20% | 24.13% |
| EBITDA | -128.13% | -25.44% | -25.59% | -8.54% | 25.31% |
| EPS Basic | -40.68% | 35.13% | 41.59% | 45.74% | 52.07% |
| Normalized Basic EPS | -41.35% | 27.70% | 35.81% | 46.54% | 52.20% |
| EPS Diluted | -40.68% | 35.13% | 41.59% | 45.74% | 52.07% |
| Normalized Diluted EPS | -41.35% | 27.70% | 35.81% | 46.54% | 52.20% |
| Average Basic Shares Outstanding | 62.59% | 62.78% | 74.32% | 72.21% | 41.86% |
| Average Diluted Shares Outstanding | 62.59% | 62.78% | 74.32% | 72.21% | 41.86% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |